Source: Annual Congress 2004 - New and emerging pharmacological strategies in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Bousquet, G. Ayre, M. Blogg (Montpellier, France; Horsham, United Kingdom). Omalizumab added to best standard care reduces exacerbations in patients with severe persistent asthma according to GINA 2002 classification. Eur Respir J 2004; 24: Suppl. 48, 1390

Member's Comments

No comment yet.

Related content which might interest you: The application of GINA guidelines results in a reduced number of exacerbations in asthmatic patients Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009 High risk COPD patients cost less if treated according to GOLD 2011 recommendations Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 COPD severity analysis according to current evaluation criteria – National survey Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Use of GINA classification of asthma severity in general practice Source: Annual Congress 2003 - Recognition, management and assessment of asthma including severe asthma Year: 2003 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Sputum assessment in asthma management does not improve disease control when GINA step-up treatment is used in mild-to-moderate patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Usefulness of severity predictive scores in COPD exacerbations in hospitalized patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Improvement in symptoms, wheezing and pulmonary function tests of asthmatic patients due to application of GINA in their treatment Source: Eur Respir J 2006; 28: Suppl. 50, 842s Year: 2006 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Defining acute asthma severity – how do worldwide asthma guidelines compare? Source: International Congress 2018 – The bad and the ugly in paediatric asthma: comorbidities and exacerbations Year: 2018 Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005 Acute severe asthma: evidence-based management of asthma exacerbations Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond Year: 2008 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003